Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | CNR1 | P21554 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13935922 | 0.87 | SIGMAR1 (0.71) | SIGMAR1EPHX1SMYD3SMN1; SMN2ALDH1A1 | |
| SCHEMBL25501931 | 0.86 | SMN1; SMN2 (0.55) | SIGMAR1EPHX1GAASMYD3TSHR | |
| SCHEMBL12819735 | 0.85 | SMYD3 (0.56) | SIGMAR1EPHX1GAASMYD3SMN1; SMN2 | |
| SCHEMBL10304524 | 0.84 | SIGMAR1 (0.67) | SIGMAR1EPHX1GAASMN1; SMN2ALDH1A1 | |
| SCHEMBL19739051 | 0.83 | SIGMAR1 (0.70) | SIGMAR1SMYD3SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL13661594 | 0.82 | SIGMAR1 (0.64) | SIGMAR1SMYD3SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL1314827 | 0.81 | SIGMAR1 (0.72) | SIGMAR1EPHX1SMYD3SMN1; SMN2ALDH1A1 | |
| SCHEMBL1316135 | 0.81 | SIGMAR1 (0.72) | SIGMAR1EPHX1SMYD3SMN1; SMN2ALDH1A1 | |
| SCHEMBL975896 | 0.80 | SIGMAR1 (0.73) | SIGMAR1SMN1; SMN2ALDH1A1KMT2AHPGD | |
| SCHEMBL1316096 | 0.79 | SIGMAR1 (0.69) | SIGMAR1EPHX1SMYD3SMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | Epizyme, Inc. (US) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200123142-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | SIGMAR1 371/4885EPHX1 3678/4885GAA 3339/4885 |
| US-20170362191-A1 | Substituted Cyclohexylamine Compounds | SMYD3, SMYD2, SNRPD3 | SIGMAR1 371/4885EPHX1 3678/4885GAA 3339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.